• GAGANDEEP SINGH St. Soldier Institute of Pharmacy, Lidhran Campus, Behind NIT (R. E. C), Jalandhar-Amritsar by Pass NH-1 Jalandhar 144011, Punjab, India
  • NARINDER SINGH St. Soldier Institute of Pharmacy, Lidhran Campus, Behind NIT (R. E. C), Jalandhar-Amritsar by Pass NH-1 Jalandhar 144011, Punjab, India
  • AJEET PAL SINGH St. Soldier Institute of Pharmacy, Lidhran Campus, Behind NIT (R. E. C), Jalandhar-Amritsar by Pass NH-1 Jalandhar 144011, Punjab, India
  • AMAR PAL SINGH St. Soldier Institute of Pharmacy, Lidhran Campus, Behind NIT (R. E. C), Jalandhar-Amritsar by Pass NH-1 Jalandhar 144011, Punjab, India



Mmucormycosis, Types, Epidemiology, Taxonomy, Treatments


Mucormycosis is a new angioinvasive infection caused by the ubiquitous filamentous fungus of the Mucorales order of the Zygomycete class. Mucormycosis has emerged as the third most prevalent invasive mycosis in patients undergoing hematological and allogeneic stem cell transplantation, following candidiasis and aspergillosis. Sporangiospores must be inhaled on a daily basis. Members of the Mucorales are very infrequent in nasal mucus, indicating that spores in airway mucus are removed via mucociliary transport or that there is a minimal degree of airborne contamination.


Download data is not yet available.


Ribes JA, Vanover Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2002;13:236–301.

Andrews DR, Allan A, Larbalestier RI. Tracheal mucormycosis. Ann Thorac Surg 1997;63:230–2.

Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother 2006;50:96–103.

Bauer H, Flanagan JF, Sheldon WH. The effects of metabolic alterations on experimental rhizopus orayzae (mucormycosis) infections. Yale J Biol Med 1956;29:23–32.

Hibbett DS, Binder M, Bischoff JF. A higher-level phylogenetic classification of the fungi. Mycol Res 2007;111:509–47.

Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, et al. Mucormycosis in renal transplant recipients: a review of 174 reported cases external icon. BMC Infect Dis 2017;17:283.

Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in sudan external icon. J Clin Microbiol 2002;40:1031–6.

Abramowitz I. Fatal perforations of the stomach due to mucormycosis of the gastrointestinal tract. S Afr Med J 1964;38:93–4.

Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and external management icon. Clin Microbiol Rev 2005;18:556-69.

Voigt K, Cigelnik E, O’Donnell K. Phylogeny and PCR identification of clinically important zygomycetes based on nuclear ribosomal DNA sequence data. J Clin Microbiol 1999;37:3957–64.

Voigt K, Wostemeyer J. Phylogeny and origin of 82 zygomycetes from all 54 genera of the mucorales and mortierellales based on combined analysis of actin and translation elongation factor EF-1alpha genes. Gene 2001;270:113–20.

Dannaoui E, Garcia Hermoso D. The zygomycetes. In: Kavanagh K. ed. New insights in medical mycology. Springer: New York; 2007. p. 159–83.

Sugar A. Agents of mucormycosis and related species. In: Mandell GL, Bennett JE, Dolin R. eds. Principles and practice of infectious diseases. 6th edn. New York: Elsevier; 2005. p. 2973–84.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosisexternal icon. Clin Infect Dis 2012;54:23-34.

James TY, Kauff F, Schoch CL. Reconstructing the early evolution of Fungi using a six-gene phylogeny. Nature 2006;443:818–22.

Marty FM, Cosimi LA, Baden LR. Breakthrough mucormycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950–2.

Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004;10:31–47.

Andrews PA, Abbs IA, Koffman CG, Ogg CS, Williams DG. Mucormycosis in transplant recipients: possible case transmission and potentiation by cytomegalovirus. Nephrol Dial Transplant 1994;9:1194–6.

Talmi YP, Goldschmied Reouven A, Bakon M. Rhino-orbital and rhino-orbito-cerebral mucormycosis. Otolaryngol Head Neck Surg 2002;127:22–31.

Anand VK, Alemar G, Griswold JA. Intracranial complications of mucormycosis: an experimental model and clinical review. Laryngoscope 1992;102:656–62.

Lass Florl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 2009;15:60–5.

Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology. Diagnosis and treatment. Med Mycol 2007;45:321–46.

Dickinson M, Kalayanamit T, Yang CA, Pomper GJ, Franco Webb C, Rodman D. Cutaneous zygomycosis (mucormycosis) complicating endotracheal intubation: diagnosis and successful treatment. Chest 1998;114:340–2.

Rogers TR. Treatment of mucormycosis: current and new options. J Antimicrob Chemother 2008;61:35–9.

Barnett J, Behr W, Reich H. An amphotericin B-resistant case of rhinocerebral mucormycosis. Infection 1985;13:134–6.

Pongas GN, Lewis RE. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? External Icon Clin Microb Infec 2009;15:93-7.

John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosisexternal icon. Clin Microbiol Infect 2005;11:515-7.



How to Cite

SINGH, G., N. SINGH, A. P. SINGH, and A. P. SINGH. “MUCORMYCOSI (BLACK FUNGUS): A REVIEW”. International Journal of Current Pharmaceutical Research, vol. 13, no. 5, Sept. 2021, pp. 10-13, doi:10.22159/ijcpr.2021v13i5.1888.



Review Article(s)